Gold.com stock steadies as Monex deal closes and gold prices hit a one-week high

Gold.com Inc shares were little changed on Tuesday, up less than 0.1% at $36.35 in early U.S. trading, after the precious-metals dealer confirmed it had closed its acquisition of Monex Precious Metals.

Mergers and Acquisitions · Precious Metals · TSX:8698
Uber stock slips as SpotHero acquisition-talk report emerges in year-end trade

Uber stock slips as SpotHero acquisition-talk report emerges in year-end trade

Uber Technologies shares were down about 0.3% at $81.87 in afternoon trade on Wednesday, after moving between $81.60 and $82.48, following a report the company has been in talks to acquire parking reservation app SpotHero. The Information said SpotHero has raised more than $110 million and was most recently valued at about $290 million, citing PitchBook data. The Information
31 December 2025
··
AI Stocks Today (Dec. 25, 2025): Nvidia’s Groq Deal, Snowflake’s M&A Talks, UiPath’s Index Boost, and Meta’s WhatsApp AI Clash

AI Stocks Today (Dec. 25, 2025): Nvidia’s Groq Deal, Snowflake’s M&A Talks, UiPath’s Index Boost, and Meta’s WhatsApp AI Clash

December 25, 2025 — It’s Christmas Day, U.S. markets are taking a breather, and yet the AI-stock news cycle is doing what it always does: refusing to sleep. With investors digesting a holiday-thinned week of announcements, today’s biggest AI-stock narratives revolve around AI inference hardware, software consolidation, and regulatory pressure on AI distribution channels—the plumbing that decides which chatbots can reach billions of users.
25 December 2025
······
Dynavax Technologies (DVAX) Stock Jumps on Sanofi’s $2.2B Cash Buyout Offer: Latest News, Forecasts, and What Comes Next (Dec. 24, 2025)

Dynavax Technologies (DVAX) Stock Jumps on Sanofi’s $2.2B Cash Buyout Offer: Latest News, Forecasts, and What Comes Next (Dec. 24, 2025)

Dynavax Technologies Corporation is the center of the biotech tape on Wednesday, December 24, 2025, after Sanofi announced a deal to acquire the vaccine maker in an all-cash transaction valued at roughly $2.2 billion. The headline number investors are keying on: $15.50 per share in cash—a bid that reframes the near-term outlook for DVAX stock from “earnings and pipeline execution” to “deal timeline and closing risk.” Sanofi+1
24 December 2025
···
ABIVAX Société Anonyme Stock (ABVX) Jumps on Fresh Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Takes EffectABIVAXABIVAX Société Anonyme Stock (ABVX) Jumps on Fresh Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Takes Effect

ABIVAX Société Anonyme Stock (ABVX) Jumps on Fresh Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Takes EffectABIVAXABIVAX Société Anonyme Stock (ABVX) Jumps on Fresh Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Takes Effect

PARIS / NEW YORK — December 22, 2025 — ABIVAX Société Anonyme stock is back in the spotlight on Monday after renewed takeover chatter tied to U.S. pharma giant Eli Lilly—arriving the same morning Abivax’s addition to the Nasdaq Biotechnology Index becomes effective. The combination is fueling a sharp move in ABVX shares and re-igniting debate about whether 2025’s biotech breakout is now morphing into an M&A story.
22 December 2025
··
ABIVAX (ABVX) Stock Surges on Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Kicks In — News, Forecasts and Outlook (Dec. 22, 2025)

ABIVAX (ABVX) Stock Surges on Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Kicks In — News, Forecasts and Outlook (Dec. 22, 2025)

December 22, 2025 — ABIVAX Société Anonyme is back in the spotlight today, with traders juggling two storylines that can move a biotech stock fast: renewed takeover speculation involving Eli Lilly and Abivax’s addition to the Nasdaq Biotechnology Index, effective before today’s market open. GlobeNewswire+2Investing.com+2
22 December 2025
····
Amicus Therapeutics (FOLD) Stock Week Ahead: $14.50 BioMarin Buyout Puts the Deal Spread—and New Filings—Front and Center (Dec. 22–26, 2025)

Amicus Therapeutics (FOLD) Stock Week Ahead: $14.50 BioMarin Buyout Puts the Deal Spread—and New Filings—Front and Center (Dec. 22–26, 2025)

As of Sunday, December 21, 2025, Amicus Therapeutics, Inc. is no longer trading like a “typical biotech story stock.” After BioMarin’s all-cash $14.50-per-share takeover agreement, FOLD has effectively become a deal-driven, merger-arbitrage name—meaning next week’s action is likely to hinge less on quarterly fundamentals and more on the probability, timing, and conditions of closing. SEC+1
22 December 2025
····
ServiceNow (NOW) Stock Week Ahead: Armis Deal Chatter, Moveworks Integration, 5-for-1 Split Fallout, and Fresh Analyst Targets

ServiceNow (NOW) Stock Week Ahead: Armis Deal Chatter, Moveworks Integration, 5-for-1 Split Fallout, and Fresh Analyst Targets

ServiceNow, Inc. heads into the week of December 22–26, 2025 with momentum in its product narrative—but also with headline risk that has recently dominated the stock. The company has closed its largest acquisition to date, announced a security-focused buyout of identity specialist Veza, and completed a 5-for-1 stock split—all while markets digest reports that ServiceNow is in advanced talks to buy cybersecurity firm Armis for up to $7 billion. Reuters+3ServiceNow Newsroom+3ServiceNow Newsroom+3
21 December 2025
··
Amicus Therapeutics (FOLD) Stock Jumps on BioMarin’s $4.8B Buyout: Latest News, Forecasts, and Deal Analysis as of Dec. 20, 2025

Amicus Therapeutics (FOLD) Stock Jumps on BioMarin’s $4.8B Buyout: Latest News, Forecasts, and Deal Analysis as of Dec. 20, 2025

Amicus Therapeutics, Inc. has become one of the most closely watched rare-disease stocks heading into the final stretch of 2025 after BioMarin Pharmaceutical announced a definitive agreement to acquire Amicus in an all-cash transaction valued at about $4.8 billion. The offer price—$14.50 per share in cash—instantly reset the “center of gravity” for FOLD shares and shifted investor focus from traditional biotech catalysts to merger timing, regulatory approvals, and closing risk. SEC+1
21 December 2025
··
Warner Bros. Discovery Stock (WBD) Forecast: Netflix Merger vs. Paramount’s $30 Bid Puts Shares in Deal-Driven Limbo (Dec. 20, 2025)

Warner Bros. Discovery Stock (WBD) Forecast: Netflix Merger vs. Paramount’s $30 Bid Puts Shares in Deal-Driven Limbo (Dec. 20, 2025)

Warner Bros. Discovery stock is no longer trading like a “normal” media equity. As of this weekend, WBD shares are moving like a merger-arbitrage instrument, tethered to two competing takeover paths: Netflix’s signed deal for WBD’s Studios + Streaming assets and Paramount Skydance’s hostile all-cash tender offer for the entire company. Reuters+2Warner Bros. Discovery IR+2
21 December 2025
···
1 2 3 4 5 … 7
Follow on Google News
Add as preferred source Open in Google News